STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026

(NYSE: STE) STERIS plc announced that it will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET on August 6, 2026. The conference call can be accessed live at www.steris-ir.com or by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally. A press release detailing financial results will be issued after the U.S. market closes on August 5, 2026. A replay of the conference call will be available beginning at 12:00 p.m. ET on August 6, 2026, at www.steris-ir.com or via phone using access code 9090649. STERIS is described as a leading global provider of products and services that support patient care with an emphasis on infection prevention. The company cautions that the release and conference call may contain forward-looking statements, including expectations, forecasts, and estimates. Many factors are cited that could cause actual results to differ materially from those in the forward-looking statements.

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2026, AND REVISES 2026 FULL YEAR OPERATING RESULTS FORECAST

(NYSE: UHS) Universal Health Services, Inc. announced reported net income attributable to UHS of $358.4 million, or $5.98 per diluted share, during the second quarter of 2026, compared to $353.2 million, or $5.43 per diluted share, during the second quarter of 2025. Net revenues increased by 8.3% to $4.638 billion during the second quarter of 2026, as compared to $4.284 billion during the second quarter of 2025. EBITDA net of NCI was $680.2 million during the second quarter of 2026, compared to $651.4 million during the second quarter of 2025, and adjusted EBITDA net of NCI was $677.9 million versus $642.9 million. During the first six months of 2026, reported net income attributable to UHS was $707.1 million, or $11.63 per diluted share, compared to $669.9 million, or $10.23 per diluted share, in the comparable period of 2025, with net revenues rising by 8.9% to $9.133 billion. The company repurchased 1.890 million shares at an aggregate cost of approximately $320.3 million during the second quarter of 2026, and 2.565 million shares at an aggregate cost of approximately $447.5 million during the first six months of 2026. As of June 30, 2026, UHS had $1.272 billion of available borrowing capacity under its $1.5 billion revolving credit facility, and $400 million of borrowing capacity pursuant to a delayed draw term loan A, expected to be drawn upon the closing of the acquisition of Talkspace, Inc. The company projects revised 2026 forecasted net revenues between $18.501 billion and $18.762 billion, adjusted EBITDA net of NCI between $2.610 billion and $2.717 billion, and adjusted EPS-diluted between $22.28 and $23.65 per share.

Welltower Reports Second Quarter 2026 Results

(NYSE: WELL) Welltower Inc. announced results for the quarter ended June 30, 2026, reporting net income attributable to common stockholders of $0.61 per diluted share. The company reported quarterly normalized funds from operations attributable to common stockholders of $1.60 per diluted share, an increase of 25.0% over the prior year. Year-to-date, Welltower closed or is under contract to close $15.5 billion of pro rata gross investments, including $9.4 billion completed in the six months ended June 30, 2026, and $6.1 billion closed or under contract to close subsequent to quarter end, excluding development funding. The company completed $843 million of pro rata dispositions and loan repayments during the second quarter, including $561 million of Outpatient Medical dispositions and $155 million of loan repayments. As of June 30, 2026, Welltower reported Net Debt to Adjusted EBITDA of 2.99x and approximately $9.5 billion of available liquidity. In July 2026, the company issued C$1.15 billion of senior unsecured notes with a weighted-average coupon of 3.95%. The Board of Directors announced a 15% increase in the quarterly dividend to $0.85 per share.

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

(NASDAQ:ORGO) Organogenesis Holdings Inc. announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the management of complex venous leg ulcers (VLUs). The 206-patient trial randomized 1:1 to Affinity + SoC or SoC alone and followed patients for 24 weeks after a four-week run-in period. Statistically significant improvements in wound closure at weeks 12 and 16 for the Affinity + SoC group were demonstrated (p<0.05) across two wound duration strata: wounds present for more than 6 months and wounds present for more than 24 months. The results were published in the Journal of Wound Care and reinforce the benefit of Affinity in the hardest-to-heal wounds. This VLU data set complements existing Affinity evidence in diabetic foot ulcers (DFUs). The company states that these results present a meaningful step forward for patients, clinicians, and payers. Forward-looking statements include expectations of benefits to patients from using Affinity and to the Company from the sale of Affinity.

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

(NASDAQ:BNGO) Bionano Genomics, Inc. announced that it will host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2026 and to highlight recent corporate progress. The conference call and webcast will be accessible via the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano’s investor relations website at https://ir.bionano.com/ for at least 30 days. The company contact is Al Luderer, Chairman & Interim CEO, and the investor relations contact is Webb Campbell of Gilmartin Group. No financial figures, production volumes, or counterparties are disclosed in the announcement. The announcement provides details for accessing the webcast and replay.

ERAS Stock Drop: If You Incurred Significant Losses in Erasca, Inc., Contact Robbins LLP for Information About Recovering Your Losses

(NASDAQ:ERAS) A class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. securities between January 14, 2025 and April 26, 2026. The complaint alleges that Erasca, Inc. failed to disclose it was at risk of violating patent and trade secret protections, specifically regarding ERAS-0015's preclinical data and comparisons to Revolution Medicines, Inc. On April 27, 2026, Erasca disclosed in a Form 8-K that it had received a letter from legal counsel for RevMed alleging that ERAS-0015 infringes a RevMed patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca's common stock fell from $21.49 per share on April 24, 2026, to $19.15 per share on April 27, 2026. Shareholders who wish to serve as lead plaintiff for the class must submit their papers to the court by August 10, 2026. Robbins LLP has helped restore more than $1 billion in value to shareholders, secured some of the largest recoveries in shareholder derivative litigation history, and achieved governance reforms at over 400 Fortune 1000 companies.

Animalcare Group

(AIM:ANCR) Animalcare Group is subject to a proposed acquisition by CCP Paw 2 Limited, as announced in relation to the FTSE UK Index Series. The acquisition is contingent upon court sanctioning the scheme of arrangement. Following this, Animalcare Group (UK, constituent) will be deleted from the FTSE AIM 100 Index and FTSE AIM All-Share Index effective from the start of trading on 30 July 2026. The announcement was provided by FTSE Russell and distributed by RNS, the news service of the London Stock Exchange. For further information, FTSE Russell Client Services can be contacted at info@ftserussell.com or via regional phone numbers for Asia Pacific ex Japan, Japan, Europe, Middle East & Africa, and North America. The company projects the index changes will occur subject to court sanctioning the scheme of arrangement.

MNDR and Jospong Form Exclusive Joint Venture to Launch AI-Powered Digital Healthcare Ecosystem in Ghana

(NASDAQ: MNDR) Mobile-health Network Solutions Inc. and Jospong Group of Companies Limited announced the signing of a definitive Joint Venture (JV) agreement to establish MHNS Ghana Limited, with an initial capitalization of US$2.5 million. The capitalization comprises MNDR's proprietary technology contribution valued at US$1.225 million and Jospong's US$1.275 million cash contribution. MHNS Ghana Limited will have exclusive rights to deploy and operate MNDR's digital healthcare ecosystem in Ghana. The JV has an initial ten-year term and may be renewed for successive five-year periods by mutual written agreement. Board representation and reserved-matter protections provide joint oversight of key strategic, financial, and operational decisions. The agreement converts the parties' August 2025 Memorandum of Understanding into a funded, governed, and operational JV framework. The company projects potential expansion into additional Sub-Saharan African markets, subject to applicable regulatory approvals and mutually agreed expansion plans.

Global UAV Announces Proposed Acquisition of Nexus Peptide Sciences Inc.

(CSE: UAV) Global UAV Technologies Ltd. has entered into a letter of intent dated July 27, 2026, with Nexus Peptide Sciences Inc. to acquire all outstanding securities of Nexus. The company has agreed to issue an aggregate of 20,300,000 common shares and 7,000,000 transferable share purchase warrants to the Nexus Shareholders, with each warrant exercisable at $0.10 per share for two years following closing. Immediately before closing, there will be no more than 33,000,000 shares and 17,000,000 share purchase warrants outstanding, with such warrants to have an exercise price of $0.10 per share. The company anticipates a finder's fee of $100,000 in cash and 1,000,000 shares in connection with the transaction. Concurrently, the company intends to complete an equity financing of a minimum of $3,000,000 and a maximum of $5,000,000 on or before closing. The board of the resulting issuer will consist of five directors: three nominees of Nexus (Dr. Patrick Gunning, Dr. Mark Lindsay, and Dr. Mona Ezzat-Velinov) and two continuing directors of the company (Ron Schmitz and Tim Ko). The company projects that Chris Cherry will be appointed as Chief Financial Officer upon closing.

Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update - Correction

(OTCQB: RDGL) Vivos Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Feasibility Investigational Device Exemption (IDE) application on July 2, 2026, enabling the initiation of a first-in-human feasibility study at Mayo Clinic in Jacksonville, Florida, targeting patients with non-resectable papillary thyroid carcinoma. The study will initially enroll five patients to evaluate safety and feasibility, with the safety follow-up period reduced from five years to 24 months following FDA communications. In India, Vivos Inc. has sufficient patient data from clinical work to prepare and submit an article for publication, and anticipates receiving Drugs Controller General of India (DCGI) approval to resume human treatments under the FDA-aligned protocol by the end of 2026. The animal therapy business supports 17 certified clinics across the U.S. that have treated more than 200 small animals and horses, and has recently signed agreements with two veterinary clinics in California and one in North Carolina. Manufacturing operations at the Applied Process Engineering Laboratory (APEL) in Richland, WA are nearing completion, with IsoPet shipments for veterinary use targeted by the end of this quarter, and a contract has been executed with a supplier in India to replicate production capabilities. The company projects conducting a strategic meeting in Q4 2026 with Key Opinion Leaders to expand RadioGel ® and IsoPet ® therapy internationally, and anticipates moderate cash flow from research sales of its hydrogel. Vivos Inc. is also adding an ISO Class 7 clean room at APEL and is preparing submissions for DCGI approval to conduct a formal Phase I/II clinical trial at HGC in India.

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

(NASDAQ:ICCM) IceCure Medical Ltd. announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company's post-marketing study "ChoICE" for ProSense® cryoablation in the treatment of low-risk breast cancer, following FDA marketing authorization in October 2025. The ChoICE Study will enroll up to 400 patients across 30 U.S. sites, gathering real-world data to support further clinical adoption and broader access for eligible patients. ProSense® is cleared by the U.S. Food and Drug Administration for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery. Under the approved study design, 30 participating sites will serve both as ChoICE Study sites and as active commercial sites, enabling them to enroll and treat a total of 400 patients while also offering ProSense® cryoablation to appropriate patients who are not participating in the ChoICE Study. IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors, with primary focus areas being breast, kidney, bone, and lung cancer. The company projects that the ChoICE Study and the resulting data will support clinical and commercial adoption of ProSense® and broader patient access. The West Cancer Center & Research Institute has served the Mid-South for 47 years and continues as the leader in adult cancer care.

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

(NASDAQ: SPRC) SciSparc Ltd. announced that its board of directors has made a decision to target the agentic artificial intelligence (“AI”) market. The Company has decided to establish a Scientific Advisory Board to focus on AI and cybersecurity. SciSparc is currently evaluating opportunities and is in discussions with several companies active in the agentic AI field. The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments and owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. SciSparc, together with NeuroThera, is currently engaged in drug development programs based on THC and/or non-psychoactive CBD, including SCI-110 for the treatment of Tourette syndrome, Alzheimer's disease and agitation, and SCI-210 for the treatment of Autism Spectrum Disorder and status epilepticus. The company projects opportunities available to it in the agentic AI market. No revenue, production, or financing figures are disclosed in the announcement.

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

(NASDAQ:HRTX) Heron Therapeutics, Inc. announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the provided registration link, and participants are encouraged to dial in fifteen minutes ahead of the scheduled start time. The webcast will be available under the Investor Relations section of Heron’s website at www.herontx.com. An archive of the teleconference and webcast will be made available on Heron’s website for 60 days following the call. Heron Therapeutics, Inc. is described as a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations for acute care and oncology patients. The company states that its advanced science, patented technologies, and innovative approach have allowed it to create and commercialize a portfolio of products. The news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995.

Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update

(OTCQB: RDGL) Vivos Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Feasibility Investigational Device Exemption (IDE) application on July 22, 2026, enabling the initiation of a first-in-human feasibility study at Mayo Clinic in Jacksonville, Florida, targeting patients with non-resectable papillary thyroid carcinoma. The study will initially enroll five patients to evaluate safety and feasibility, with the safety follow-up period reduced from five years to 24 months following FDA feedback. In India, Vivos Inc. has sufficient patient data from clinical work to prepare and submit an article for publication and anticipates receiving Drugs Controller General of India (DCGI) approval for its Principal Investigator at Healthcare Global Enterprises Hospital (HGC) to resume human treatments under the FDA-aligned protocol by the end of 2026. The animal therapy business supports 17 certified clinics across the U.S. that have treated more than 200 small animals and horses, and recently signed agreements with two veterinary clinics in California and one in North Carolina. Manufacturing validation activities are underway at the Applied Process Engineering Laboratory (APEL) in Richland, WA, with IsoPet shipments for veterinary use targeted by the end of this quarter, and a contract executed with a supplier in India to replicate production capabilities. Vivos Scientific India LLP positions the company for efficient supply to India and neighboring markets, and the company is offering its polymer and sterile hydrogel for research sale, having received interest from universities and major pharmaceutical companies. The company projects that these efforts will generate moderate cash flow while remaining focused on advancing treatments for cancerous tumors.

Share option award

(AIM: IXI) IXICO plc announced the issuance of a total of 400,000 share options to advisors of the Company. The award follows the approval of a non-employee sub-plan to the IXICO share option plan by shareholders at the general meeting of the Company on 16 April 2026. These options have vesting criteria aligned with the services to which the advisors are contracted over a two-year period. The options have an exercise price of £0.01. IXICO has supported hundreds of neurological clinical trials and analysed hundreds of thousands of scans. The IXI TM platform is tailor-made for neurological disease, reliably processing data from global trials and precisely measuring key imaging biomarkers associated with diseases such as Alzheimer's, Huntington's and Parkinson's.

Genvor’s Antimicrobial Peptides Advance into Sugar Beet Research

(OTCQB: GNVR) Genvor, Inc. announced that its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, storage, and processing. The research is being conducted under the ARS Sustainable Sugar Beet Research Initiative, with Genvor serving as a collaborator contributing its antimicrobial peptides for evaluation. The project focuses on the development and evaluation of antimicrobial peptide technologies for agriculture, aiming to advance peptide-based approaches to crop protection. USDA-ARS researchers will evaluate whether Genvor’s antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction. The collaboration is expected to generate research data that may inform future peptide-based strategies for crop protection, post-harvest quality, and processing efficiency. Genvor is powered by its proprietary BioCypher™ platform and patented peptides. Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness.

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

(NASDAQ:CTMX) CytomX Therapeutics, Inc. announced the appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors. Dr. Fuchs has more than three decades of experience across academia and global drug development, including advancing multiple cancer therapies from early research through approval. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM), and is initially being developed for the treatment of metastatic colorectal cancer. CX-801 is a masked interferon alpha-2b PROBODY cytokine initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with Amgen, Regeneron and Moderna. The company projects that Varseta-M will advance towards pivotal studies and ultimately to regulatory approval.

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

(NASDAQ:EIKN) Eikon Therapeutics, Inc. announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC). TeLuRide-008 (NCT07365319) is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered intravenously in combination with pembrolizumab and histology-appropriate chemotherapy to systemic therapy-naïve participants with Stage 4 non-squamous or squamous NSCLC. The specific chemotherapy for non-squamous histology is pemetrexed plus either carboplatin or cisplatin, while for squamous histology it is carboplatin plus paclitaxel or nab-paclitaxel. TeLuRide-008 is the second registrational phase 2/3 trial for EIK1001, following TeLuRide-006 (NCT06697301), which was initiated in May of 2025 and is enrolling patients with advanced malignant melanoma. EIK1001 has been studied in over 500 patients and observed to be well-tolerated to date, both as a monotherapy and in combination with PD-(L)1-specific antibody-based therapy. The company projects anticipated data readouts, expected milestones, and business objectives for 2026 and beyond.

Healthcare Triangle Creates "Purpose Health" to Monetize AI Demand and Accelerate Shareholder Returns

(NASDAQ:HCTI) Healthcare Triangle, Inc. announced the appointment of Sumit Ganguli as Chairman and Chief Executive Officer of Purpose Health, Inc., HCTI's wholly owned, AI-led healthcare technology services subsidiary. Ganguli previously scaled a Healthcare & Technology focused company 18–fold to approximately $175 M from 2009 to 2024, and directed multi-year healthcare client engagements valued between $25 million and $300 million. Purpose Health is focusing on developing competency partnerships with leading Electronic Health Record (EHR) vendors, global hyperscale cloud providers, and AI market leaders. Ganguli grew his prior organization to almost four thousand colleagues across multiple geographies and served as Vice Chairman and Board Member from October 2024 to July 2026. He worked with India's leading Technology University, Indian Institute of Technology, Madras, to build and deploy Reinforced Learning based AI Monitoring & Operations tool at multiple clients. The company projects multi-year recurring revenue streams and aims to deliver repeatable AI–led solutions and outcome-oriented partnerships to providers, payors, life science & med-tech clients in the US & internationally. Forward-looking statements in the release note that actual results could differ materially from those anticipated.

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

(NYSE: BHVN) Biohaven Ltd. and Yale University announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in trade secret misappropriation and breach of contract litigation against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC, awarding a combined $4 million in damages. The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret relating to its "MODA" targeted protein degradation platform, and that RA Capital separately breached its 2019 confidentiality agreement with Yale. The damages awarded included $2 million to Yale for RA Capital's breach of contract, and $1 million each to Yale and Biohaven for trade secret misappropriation. The case was filed in March 2023 and proceeded to a jury trial beginning July 20, 2026, with the verdict returned on July 24, 2026. Dr. David Spiegel, a professor at Yale, developed the MODA platform and presented it at Yale's Lifesciences Pitchfest in 2018. RA Capital entered into a confidentiality agreement with Yale in April 2019 to evaluate a potential investment in the technology, but negotiations ended without an agreement in August 2019. Biohaven licensed the MODA platform from Yale to develop and commercialize the technology.

Company News in Context